Newsroom

Extra! Extra!
Read all about it!

Welcome to our Newsroom, your go-to source for the latest updates on Galapagos. Explore press releases, insightful blogs, and access our resource hub, complete with company materials, designed to provide media and journalists with comprehensive information about our company’s innovations and milestones

Press releasesDownload Center

The latest

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos’ product candidate GLPG5101 is produced using the company’s innovative, decentralized T-cell manufacturing platform.

Read more

The latest

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Galapagos and Adaptimmune Therapeutics announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune’s next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos’ decentralized cell manufacturing platform

Read more

The latest

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

Galapagos and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the U.S.

Read more

STORIES

Press releases

Galapagos creates new subscription right plans

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription…
View All Press Releases

Follow our journey

Subscribe to receive our press releases

Do you want to stay up to date on our journey, as we are pioneering for patients?

Subscribe to our press releasesContact Media Relations